证券代码：833575 证券简称：康乐卫士 公告编号：2023-172 北京康乐卫士生物技术股份有限公司 董事会 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整 性承担个别及连带法律责任。 北京康乐卫士生物技术股份有限公司（以下简称"公司"）于 2023 年 9 月 5 日收到保荐机构中信证券股份有限公司（以下简称"中信证券"） 出具的关于更 换保荐代表人的书面函告。 中信证券为公司向不特定合格投资者公开发行股票并在北京证券交易所上 市的保荐机构，原指定胡朝峰先生、赵洞天先生担任持续督导保荐代表人，履行 持续督导职责，持续督导期间至 2026 年 12 月 31 日止。现因胡朝峰先生离职， 为保证持续督导工作的有序进行，中信证券委派保荐代表人王天祺女士（简历详 见附件）接替工作，担任公司本次发行项目的保荐代表人，继续履行持续督导职 责。 本次变更后，负责公司持续督导工作的保荐代表人为赵洞天先生和王天祺女 士。本次变更不影响中信证券对公司的持续督导工作，公司董事会对胡朝峰先生 在担任公司保荐代表人期间所做的工作表示衷心的感谢！ 特此 ...

证券代码：833575 证券简称：康乐卫士 公告编号：2023-171 北京康乐卫士生物技术股份有限公司 公司于 2023 年 6 月 12 日召开了第四届董事会第二十次会议、第四届监事会 第十九次会议，于 2023 年 6 月 29 日召开了 2023 年第七次临时股东大会，审议 通过了《关于回购注销部分股权激励计划限制性股票方案及调整回购数量、回购 价格的议案》《关于拟变更注册资本及修订<公司章程>的议案》。 根据《北京证券交易所股票上市规则（试行）》《北京证券交易所上市公司持 续监管指引第 3 号——股权激励和员工持股计划》等法律法规、规范性文件以及 公司《限制性股票激励计划（草案）》相关规定，公司回购注销 2 名因个人原因 离职激励对象已获授但尚未解除限售的限制性股票共计 26 万股，并相应减少注 册资本。 公司已于 2023 年 7 月 26 日在中国证券登记结算有限责任公司北京分公司办 理完毕上述 26 万股回购股份的注销手续。本次回购股份注销完成后，公司总股 本由 28,120 万股减少至 28,094 万股，注册资本由 28,120 万元减少至 28,094 万元。 二、工商变更登记情况 公司 ...

Capital Increase and Shareholder Information - The company completed a capital increase by distributing 140,600,000 shares to all shareholders at a ratio of 1:1, based on a total share capital of 140,600,000 shares as of the record date [8]. - The total share capital increased from 140.6 million shares to 281.2 million shares after a rights issue, with a 1:1 bonus share distribution implemented on May 26, 2023 [105]. - The company has a total of 8,167 shareholders after the recent share capital increase [104]. - The company has a total of 133,730,680 unrestricted shares, accounting for 47.56% of the total share capital [103]. - The company has 99,734,660 restricted shares, which represent 52.44% of the total share capital [103]. Financial Performance - The company reported a revenue of ¥838,955,730, representing a 66.90% increase compared to ¥502,654,770 in the same period last year [36]. - The net loss attributable to shareholders was ¥142,929,069, a slight improvement of 2.37% from a loss of ¥146,402,622 in the previous year [36]. - The company's total assets increased by 3.68% to ¥1,434,144,804 compared to ¥1,383,301,275 at the end of the previous year [37]. - The total liabilities decreased by 16.89% to ¥373,284,367 from ¥449,148,076 at the end of the previous year [37]. - The company's cash flow from operating activities showed an improvement, with a net outflow of ¥91,504,038, a 27.42% reduction from the previous year's outflow of ¥126,067,191 [38]. - The weighted average return on equity was -14.89%, compared to -12.79% in the previous year, indicating ongoing challenges in profitability [36]. Research and Development - The company has 10 recombinant human vaccine projects under research, with several HPV vaccines entering phase III clinical trials [42]. - The company has obtained 32 invention patents as of June 30, 2023, indicating a strong focus on innovation [43]. - The company is actively investing in R&D and technological innovation to enhance its product pipeline and develop innovative vaccines [45]. - The company is focusing on the development of various HPV vaccines, including the nine-valent HPV vaccine for male indications, which officially started in December 2022 [45]. - The company has completed the three-dose vaccination for all participants in the Phase III clinical trial of the trivalent HPV vaccine and has entered the case monitoring follow-up phase [45]. Market and Competitive Environment - The Chinese HPV vaccine market is expected to expand rapidly due to low current vaccination rates and government support for including HPV vaccines in national immunization programs [50]. - The public's awareness of the necessity and role of vaccination is increasing, which is expected to boost the domestic vaccine market [48]. - The company is facing intensified market competition for its HPV vaccines, with several competitors already having products approved and on the market [75]. Corporate Governance and Management - The company has a detailed governance structure to minimize the influence of the actual controller on decision-making processes [76]. - The actual controller of the company indirectly controls 30.58% of the voting rights, which may significantly influence major decisions [75]. - The company experienced a change in leadership, with the resignation of the chairman and CEO, who transitioned to a director role due to personal reasons [127]. - The company appointed a new CEO, Tao Ran, and a new COO, Hao Chunli, effective July 17, 2023, following the resignation of the previous general manager [133]. Financial Position and Cash Flow - The company's cash and cash equivalents decreased by 46.85% to ¥353,636,014.46 from ¥665,302,917.10 at the end of the previous year [55]. - The inventory increased by 141.77% to ¥11,289,353.23, up from ¥4,669,412.67, primarily due to increased procurement for trial production [57]. - The company's long-term borrowings decreased to zero from ¥86,364,617.82, as a result of early repayment related to the acquisition of equity [57]. - The net cash flow from operating activities improved by 27.42%, from a net outflow of CNY 126,067,190.91 to CNY 91,504,037.58 [65][66]. - The net cash flow from investing activities decreased significantly by 95.29%, from CNY 169,274,139.43 to CNY 330,577,478.50, primarily due to increased investments in vaccine clinical trials and equipment payments [65][66]. Compliance and Commitments - There are no dissenting opinions from directors, supervisors, or senior management regarding the content of the semi-annual report [17]. - The company has not undergone an audit for this semi-annual report [15]. - The company has committed to not engaging in fund occupation, which is currently being fulfilled [92]. - All disclosed commitments by the company are being fulfilled without any overdue situations as of the end of the reporting period [95]. Future Plans and Projections - The company plans to submit IND applications for the recombinant respiratory syncytial virus vaccine and the recombinant multivalent norovirus vaccine in 2024 [45]. - The company plans to redirect the remaining raised funds of 6.57 million CNY to the "Kunming Production Base Construction Costs Project" [119]. - The company anticipates continued losses for the first nine months of 2023, as its vaccine products remain in the research phase [71].

北京康乐卫士生物技术股份有限公司 关于完成工商变更登记及备案的公告 证券代码：833575 证券简称：康乐卫士 公告编号：2023-164 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整 性承担个别及连带法律责任。 一、基本情况 北京康乐卫士生物技术股份有限公司（以下简称"公司"）于 2023 年 6 月 28 日召开第四届董事会第二十一次会议、2023 年 7 月 17 日召开 2023 年第八次 临时股东大会，审议通过《关于提名非独立董事候选人的议案》《关于提名独立 董事候选人的议案》《关于修订<公司章程>的议案》；于 2023 年 7 月 17 日召开第 四届董事会第二十二次会议，审议通过《关于选举公司第四届董事会董事长、副 董事长的议案》《关于聘任公司首席执行官的议案》《关于聘任公司其他高级管理 人员的议案》《关于修订<公司章程>的议案》，并于 2023 年 8 月 3 日召开 2023 年第九次临时股东大会，最终审议通过第四届董事会第二十二次会议审议提交的 《关于修订<公司章程>的议案》。 因个别董事、高级管理人员辞职， ...

证券代码：833575 证券简称：康乐卫士 公告编号：2023-094 北京康乐卫士生物技术股份有限公司 2022 年年度报告业绩说明会预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 说明会类型 北京康乐卫士生物技术股份有限公司（以下简称"公司"）于 2023 年 4 月 20 日在北京证券交易所信息披露平台（www.bse.cn）披露了《2022 年年度报告》 及《2022 年年度报告摘要》，为方便广大投资者更深入了解公司 2022 年年度经 营业绩的具体情况，加强与投资者的互动交流，公司拟召开 2022 年年度报告业 绩说明会。 二、 说明会召开的时间、地点 （一）会议召开时间：2023 年 5 月 9 日 15:00-17:00。 （二）会议召开地点 本次业绩说明会将采用网络远程的方式举行，投资者可登陆中国证券报•中 证网（https://www.cs.com.cn/roadshow/）参与本次年报业绩说明会。 三、 参加人员 公司董事长、首席执行官：郝春利先生 公司董事、总经理： ...

Financial Performance - Revenue for the first quarter of 2023 reached CNY 254,035.40, marking a 55.25% increase from CNY 163,628.29 in the same period last year[9]. - Net profit attributable to shareholders was a loss of CNY 72,601,501.99, an improvement of 2.17% compared to a loss of CNY 74,214,708.75 in Q1 2022[9]. - The company reported a net loss of ¥1,041,710,399.33 for Q1 2023, worsening from a loss of ¥976,529,955.74 in Q1 2022[52]. - The total comprehensive income for Q1 2023 was -72,601,501.99, compared to -74,214,708.75 in Q1 2022, showing a slight improvement[54]. - The operating profit for Q1 2023 was -71,723,565.45, compared to -74,214,708.75 in Q1 2022, indicating a reduction in losses[54]. - Total operating costs for Q1 2023 were ¥72,072,542.78, down from ¥74,433,093.98 in Q1 2022, indicating a reduction of about 3.2%[53]. Cash Flow and Liquidity - Operating cash flow improved by 46.33%, with a net cash flow of -CNY 58,503,524.33 compared to -CNY 108,997,638.58 in the previous year[10]. - The net cash flow from operating activities for the first quarter of 2023 was -46,401,172.86 CNY, compared to -103,459,182.36 CNY in the same period of 2022, indicating an improvement of approximately 55%[60]. - Total cash inflow from financing activities in Q1 2023 was 280,770,000.00 CNY, significantly higher than 0 CNY in Q1 2022[60]. - The cash inflow from sales of goods and services was 1,094,994.89 CNY in Q1 2023, a significant increase from 3,000.00 CNY in Q1 2022[59]. - Cash outflows for operating activities totaled 53,411,256.84 CNY in Q1 2023, down from 107,718,960.55 CNY in Q1 2022, indicating a reduction of about 50%[60]. Assets and Liabilities - Total assets increased by 15.14% to CNY 1,592,673,826.20 as of March 31, 2023, compared to CNY 1,383,301,275.21 at the end of 2022[9]. - The company's total liabilities as of March 31, 2023, were CNY 366,802,936.79, up from CNY 352,279,455.76 at the end of 2022, marking an increase of about 4.3%[47]. - The company's debt-to-asset ratio decreased to 15.84% from 18.27% year-over-year[9]. - The total liabilities to total assets ratio as of March 31, 2023, is approximately 23.0%, indicating a stable leverage position[47]. - The company's current assets totaled CNY 804,607,545.54 as of March 31, 2023, compared to CNY 734,952,072.66 at the end of 2022, indicating an increase of about 9.5%[45]. Research and Development - R&D expenses decreased, contributing to the improved cash flow and overall financial performance[11]. - Research and development expenses for Q1 2023 amounted to ¥53,212,594.76, compared to ¥62,699,458.05 in Q1 2022, reflecting a decrease of approximately 15.2%[53]. - As of March 31, 2023, the company capitalized development expenditures amounting to RMB 28,457,495.82, with R&D expenses accounting for 72% of total expenditures[37]. - The company’s major operating activities focus on R&D, which significantly impacts the consolidated financial statements[37]. Shareholder and Corporate Governance - The total number of ordinary shares increased to 140,600,000, with significant changes in the shareholding structure[16]. - The major shareholder, Tianlangxing Holdings Group, holds 21.49% of the company's shares[20]. - The company has implemented an employee incentive plan, which has been approved by the shareholders[23]. - The company has completed timely disclosures regarding external guarantees and other significant related transactions[23]. - The company received approval from the China Securities Regulatory Commission for a public offering of shares to unspecified qualified investors, valid for 12 months from January 20, 2023[30]. Regulatory and Legal Matters - The company has no ongoing litigation or arbitration matters during the reporting period[23]. - The company has not faced any investigations or penalties during the reporting period[23]. - The company has successfully executed its commitment to timely disclosures as per regulatory requirements[23].

Clinical Trials and Vaccine Development - The company completed the Phase I clinical trial for the nine-valent HPV vaccine (male indication) with all subjects receiving three doses in February 2022[5]. - The company received approval for the clinical trial of the recombinant 15-valent HPV vaccine (E. coli) in March 2022[5]. - The company completed the full immunization of subjects in the Phase II clinical trial for the three-valent HPV vaccine in December 2022[5]. - The company’s nine-valent HPV vaccine (female indication) has completed all subjects' three-dose administration in the Phase III clinical trial[11]. - The company has completed all subject vaccinations for the Phase III clinical trial of the three-valent HPV vaccine and is currently in the case monitoring follow-up phase, conducting 30-month follow-ups[52]. - The company has received clinical trial approval for the fifteen-valent HPV vaccine project from the National Medical Products Administration, with subsequent clinical trial work primarily managed by Chengda Biology[52]. - The company is currently in phase III clinical trials for a new product, a trivalent HPV vaccine, aimed at meeting customer needs and achieving economic benefits[94]. - The company is advancing its clinical trials for the trivalent and nine-valent HPV vaccines, with the trivalent vaccine having completed Phase III trials and the nine-valent vaccine (female indication) also completing all three doses for participants[109]. - The company plans to submit a Biologics License Application (BLA) for the trivalent HPV vaccine in 2025 and for the nine-valent HPV vaccine in 2026[105]. - The company has 10 recombinant human vaccine projects under research, with several HPV vaccines in phase III clinical trials[47]. Financial Performance and Challenges - The company reported a net loss attributable to ordinary shareholders of 292,817,005.92 yuan for the reporting period, with a cumulative unremedied loss of 1,028,934,588.22 yuan[12]. - The company is in a continuous loss state and expects to increase R&D investment in the near future, indicating ongoing financial challenges[12]. - The company's operating revenue for 2022 was CNY 1,900,619.35, representing a 591.69% increase compared to CNY 274,778.78 in 2021[34]. - The net loss attributable to shareholders for 2022 was CNY -292,817,005.92, a 22.86% improvement from CNY -379,604,451.64 in 2021[34]. - The net cash flow from operating activities for 2022 was CNY -310,179,361.91, a 51.56% decline from CNY -204,653,319.82 in 2021[38]. - The company's cash and cash equivalents decreased by 44.99% year-on-year, amounting to ¥665,302,917.10, mainly due to cash outflows from daily operations and long-term asset investments[65]. - The company has not yet achieved profitability since its establishment, continuing to invest heavily in vaccine research and development[101]. - The cumulative unremedied losses are expected to continue as the company increases R&D investments[115]. Market Competition and Risks - The company is facing significant market competition with five HPV vaccines already on the market, including those from Merck and GSK[11]. - The company is facing increased market competition as it develops and commercializes its vaccine products, which may impact operational performance if it fails to optimize product structure and enhance sales networks[16]. - The HPV vaccine market demand is influenced by regional economic development, consumer spending power, and government immunization programs, posing risks of lower-than-expected commercial prospects[17]. - If the HPV vaccine is included in the national immunization program, there is a risk of further price reductions, which could compress profit margins for the company's HPV vaccine products[17]. - The company faces risks related to the completion of clinical trials and market competition, with five HPV vaccines already on the market globally[111]. - The company is expanding its clinical pipeline with innovative vaccines to mitigate risks from market competition and reliance on a single product[112]. Research and Development - The company has 32 authorized invention patents as of the end of the reporting period, which are crucial for its core competitiveness[12]. - The company is focusing on increasing R&D and technological innovation investments to develop more innovative vaccines based on its existing product pipeline[52]. - The company has established several key technology platforms, including structural antigen design, gene engineering, protein expression, and vaccine engineering[103]. - The company has invested approximately ¥221.62 million in R&D during the reporting period, with cumulative R&D investment reaching ¥756.95 million[198]. - Research and development expenses increased by 8.43% year-on-year, amounting to ¥236,680,014.70, reflecting ongoing investment in product development[67]. Corporate Governance and Management - The company’s governance structure is sound, with stable management and technical personnel, and no significant changes in its industry position or operating environment[101]. - The actual controller, Mr. Tao Tao, indirectly controls 31.24% of the voting rights through various entities, which may influence major company decisions[114]. - The company has signed agreements with core technical personnel that include confidentiality and non-compete clauses to mitigate the risk of talent loss[113]. - The company has a total of 9 board members, 3 supervisors, and 7 senior management personnel[167]. - The company has a training plan for new and existing employees to enhance overall quality and meet employee needs[178][179]. Strategic Collaborations and Partnerships - The company is collaborating with Liaoning Chengda Biological Co., Ltd. on a fifteen-valent HPV vaccine, with responsibilities divided between the two parties for clinical research and commercialization[96]. - The company has signed a contract for the development of a 15-valent HPV vaccine with Chengda Bio in January 2019, with clinical trial approval received on March 14, 2022[133]. - The company is involved in a project for a clinical and industrial base for vaccines, signed in June 2020, with multiple partners including the Yunnan Dianzhong New District Management Committee[134]. - The company has signed multiple agreements for the construction of a recombinant vaccine clinical and industrialization base, with a total investment of CNY 4,950 million from Yunnan Dazhonghengsheng and CNY 500,000 from the company itself[135]. Future Outlook and Market Expansion - The company plans to expand its HPV vaccine offerings, with several domestic vaccines expected to complete clinical trials and apply for market approval within the next five years[62]. - The company aims to enhance its product structure and economic benefits through the development of new vaccines and market expansion[103]. - The company is focusing on international market expansion and building marketing systems ahead of product launches[112]. - The company is targeting the Chinese market for its HPV vaccines, focusing on women and men with certain purchasing power, as well as the Russian market for women aged 9-26[195].

证券简称： 康乐卫士 证券代码： 833575 北京市北京经济技术开发区荣昌东街 7 号 A2 幢 201、202 北京康乐卫士生物技术股份有限公司 BEIJING HEALTH GUARD BIOTECHNOLOGY INC. 北京康乐卫士生物技术股份有限公司招股说明书 本次股票发行后拟在北京证券交易所上市，该市场具有较高的投资风险。北京证券交易所主要 服务创新型中小企业，上市公司具有经营风险高、业绩不稳定、退市风险高等特点，投资者面临较 大的市场风险。投资者应充分了解北京证券交易所市场的投资风险及本公司所披露的风险因素，审 慎作出投资决定。 保荐机构（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 联席主承销商 北京市西城区车公庄大街 4 号 2 幢 1 层 A2112 室 中国证监会和北京证券交易所对本次发行所作的任何决定或意见，均不表明其对注册申 请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的盈利能力、 投资价值或者对投资者的收益作出实质性判断或者保证。任何与之相反的声明均属虚假不实 陈述。 根据《证券法》的规定，股票依法发行后，发行人经营与收益的变化 ...

北京市北京经济技术开发区荣昌东街 7 号 A2 幢 201、202 北京康乐卫士生物技术股份有限公司 BEIJING HEALTH GUARD BIOTECHNOLOGY INC. 北京康乐卫士生物技术股份有限公司招股说明书（注册稿） 本公司的发行申请尚未经中国证监会注册。本招股说明书申报稿不具有据以发行股票的法律效 力，投资者应当以正式公告的招股说明书全文作为投资决定的依据。 本次股票发行后拟在北京证券交易所上市，该市场具有较高的投资风险。北京证券交易所主要 服务创新型中小企业，上市公司具有经营风险高、业绩不稳定、退市风险高等特点，投资者面临较 大的市场风险。投资者应充分了解北京证券交易所市场的投资风险及本公司所披露的风险因素，审 慎作出投资决定。 保荐机构（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 联席主承销商 北京市西城区车公庄大街 4 号 2 幢 1 层 A2112 室 证券简称： 康乐卫士 证券代码： 833575 中国证监会和北京证券交易所对本次发行所作的任何决定或意见，均不表明其对注册申 请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的盈利能 ...